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Cancer is the second leading cause of death in the United States. Cisplatin is one 
of the well-known anti-cancer agents used to treat testicular and ovarian cancers. It 
mainly binds to the DNA bases, which leads to cell death. The cytotoxic activity of the 
cisplatin analogs is due to the interaction of platinum with nucleotides like adenine at N7 
or N1 position and guanine at N7 position. Guanine is the primary target for cisplatin 
analogs whereas adenine is the secondary target. Cisplatin analogs, [Pt(Me5dien)(D2O)]2+ 
[Me5dien = N,N,N’,N’,N’’-pentamethyl diethylene triamine] and [Pt(dien)(D2O)]2+ 
[dien=diethylene triamine] were synthesized and their effects on AMP and GMP were 
studied using NMR spectroscopy.  The experiments were conducted to examine the 
effects of bulk on 5’-GMP and 5’-AMP. The results suggest that bulk slows down the 
reaction with AMP more than with that of GMP. The order of reactivity is Pt(dien)(GMP) 
> Pt(dien)(AMP) > Pt(Me5dien)(GMP) > Pt(Me5dien)(AMP). The reaction of the 
[Pt(Me5dien)(D2O)]2+ complex with AMP leads to multiple products, some of which 
appear to be due to coordination at N1 instead of N7. 
1 
 
1. INTRODUCTION 
Cancer is the second leading cause of death in the United States. About one-half 
of all men and one-third of all women in the US will develop cancer during their 
lifetimes. Today, millions of people are living with cancer or have had cancer (American 
Cancer Society [ACS], n.d.). Thirteen percent of all the deaths around the world are due 
to cancer. Uncontrolled and unregulated division of cells leads to the formation of a 
tumor, a solid mass of cells. Cancer is also known as ‘malignant neoplasm’. Tumors may 
be benign, i.e., non-cancerous, and do not spread to the adjacent tissues whereas 
malignant tumors are cancerous and spread to different parts of the body through blood 
and lymph. There are different kinds of cancers which can develop in almost any organ or 
tissue, such as the lung, colon, breast, skin, bones, or nerve tissue.  
1.1 Causes of Cancer 
Viral and chemical carcinogens 
As of today, specific substances that cause cancer are coal tars and their 
derivatives like benzene, some hydrocarbons, aniline, asbestos, and many others (ACS, 
n.d.). Ionizing radiation from a variety of sources, such as UV rays from the sun, is 
known to cause skin cancer. To ensure the public safety, the government has set safety 
standards for many substances, including benzene, asbestos, hydrocarbons in the air, 
arsenic in drinking water, and radiation. Several viruses are linked to cancer development 
in humans, including:  
• Prolonged infection by hepatitis B or C viruses can lead to liver cancer. 
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• One of the herpes viruses, the Epstein-Barr virus, causes infectious 
mononucleosis and has been linked to non-Hodgkin lymphomas and 
nasopharyngeal cancer.  
• People with human immunodeficiency virus (HIV) have increased risk of 
developing cancers, especially Kaposi sarcoma and non-Hodgkin lymphoma. 
• Human papilloma viruses (HPV’s) have been linked to many cancers, especially 
those of the cervix, vulva, vagina, anus, and penis.  
Oncogenes and tumor suppressor genes 
During the 1970s, scientists discovered two particularly important families of genes 
related to cancer: oncogenes and tumor suppressor genes. 
Oncogenes:  
These genes cause cells to grow out of control and become cancer cells. They 
are formed by changes or mutations of certain normal genes of the cell called proto-
oncogenes. Proto-oncogenes are the genes that normally control how often a cell 
divides and the degree to which it differentiates or specializes in a specific function in 
the body (ACS, n.d.). 
Tumor suppressor genes:  
These genes are normal genes that control cell division, repair DNA errors, 
and tell cells when to die, a process known as apoptosis or programmed cell death. 
When tumor suppressor genes do not work properly, cells can grow out of control, 
which can lead to cancer (ACS, n.d.). 
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The treatment option for various cancers is by surgery. If surgery cannot remove 
all of the cancer, the other options include radiation, chemotherapy, or both. Some 
cancers require a combination of surgery, radiation, and chemotherapy (ACS, n.d.). 
Radiation therapy includes the usage of ionizing radiation, which damages the 
DNA of exposed cells or tissue. According to the American Cancer Society (n.d.), 
Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells by 
impeding their growth and division (ACS, n.d.). It includes the use of different drugs 
either individually or in combination. Anticancer activity of these drugs is due to 
alteration of DNA structure by binding to it covalently. Anticancer agents are rarely used 
singly; they are mostly used in the combination of other anticancer agents. For example, 
5-fluoro uracil and Cisplatin or cis-DDP, when given in the combination showed 
increased DNA adduct formation. They are not as effective when used separately as they 
are in combination. Cisplatin was one of the well-known drugs used in the treatment of 
cancer.  
1.2 Discovery of cisplatin as an anticancer agent 
Barnett Rosenberg, a biophysical scientist at University of Michigan decided to 
examine the role of electric currents in cell division. When Escherichia coli, also referred 
to as E. coli, cell growth was observed by placing them in the ammonium chloride buffer 
medium and a current applied through inert platinum electrodes, E. coli cells appeared as 
long and filamentous instead of classical sausage shape after a period of time. This affect 
was due to the inhibition of the cell division. Later, it was found that the hydrolysis 
products of platinum from the platinum electrodes were responsible for the growth 
inhibition but not the electric current.  
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Figure 1: Structure of Cisplatin or cis-DDP. (Wiltshaw & Kroner, 1976). 
The 10th group of transition metal compounds were tested for activity, of which 
the (NH4)2(PtCl6) salt was found to be more effective. Detailed chemical analysis of this 
study identified two active complexes: the neutral cis-isomer [Pt(II)(NH3)2Cl2], which 
went on to be known as cisplatin, shown in Figure 1, and a platinum(IV) analogue, as cis-
diamminetetrachloroplatinum. These molecules are responsible for inhibitory effect on 
the cancer cells. The trans forms of Pt(II) and Pt(IV) complexes were found to be 
ineffective when compared to the cis forms (Rosenberg, VanCamp, & Krigas, 1965).  
In 1968, further tests were conducted on various bacteria. Cisplatin was 
administered intra-peritoneally to mice bearing a standard murine transplantable tumor, 
sarcoma-180, which was shown to cause marked tumor regression (Rosenberg & 
Vancamp, 1969). The in-vivo tests were performed at the Chester Beatty Institute in 
London, United Kingdom. Later, US National Cancer Institute (NCI) conducted clinical 
trials on Cisplatin and it was approved by US Food and Drug Administration (FDA) in 
1978. 
The success of cisplatin led to the synthesis and biological evaluation of many 
cisplatin analogues. Much of the effort in the design of new platinum drugs was aimed 
mainly at making cisplatin-based therapy safer to patients, especially lessening or 
removing unpredictable and severe nephrotoxicity, i.e., damage to kidneys and providing 
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oral bioavailability. One other reason is to overcome tumor resistance, either acquired 
during cycles of therapy with cisplatin or intrinsic resistance. Synthesis of drugs to 
overcome these side effects has proven to be a challenging goal and led to a renewed 
optimism in translating the ‘second-generation and third-generation’ platinum drugs into 
clinical practice to provide benefit to cancer patients. 
1.3 Chemistry of Cisplatin 
Cisplatin is generally believed to exert its anticancer activity by interacting with 
DNA, inducing programmed cell death. Figure 2 shows the different binding sites for 
cisplatin. Guanine-N7 is the preferred site for initial binding of the Pt(II) complex, since 
guanine is the most nucleophilic DNA base. Both in-vitro and in-vivo, the majority of 
bifunctional DNA adducts formed are intrastrand, i.e., formed between bases on the same 
DNA strand, of which approximately 65% is GG adducts, and 25% is AG adducts. 
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Figure 2: Schematic diagram showing various binding sites available for cisplatin 
(Lippert, 1999). 
Following the success of cisplatin, many studies were performed to determine the 
structural features that are required for a platinum compound to exhibit antitumor 
activity. Michael and Hoeschele (1973) proposed the structural activity relationship for 
platinum compounds. The discoveries of Michael and Hoeschele indicated that the 
following structural criteria were necessary for platinum compounds (Michael & 
Hoeschele, 1973): 
1. The platinum compound should have two amine groups with cis geometry, as 
compounds with tsrans geometry are inactive. 
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2. The compound should have at least two leaving groups. The two groups should be 
in cis geometry with respect to each other. Leaving groups are those groups on the 
molecule that are removed most easily. 
3. The activity and toxicity of the compound depends upon the ease with which the 
leaving groups can be removed. 
4. The compound should be neutral.  
5. Compounds with less alkyl substituents have greater activity because of greater 
availability of protons on the amine group. 
Based on these studies, many newer platinum compounds were developed which 
are less toxic and less resistant compared to cisplatin. Carboplatin and Oxaliplatin are the 
results of two such modifications and are shown in Figure 3. 
 Carboplatin (Cis-diamine (1,1-cyclobutanedicarboxylato) platinum-II is mainly 
used to treat ovarian cancer apart from lung, head and neck cancers. It shows better 
antitumor activity, and it is less nephrotoxic than cisplatin, but it is more myelotoxic, i.e., 
depression in bone marrow than cisplatin (Wiltshaw & Kroner, 1976). 
Oxaliplatin [Oxalate (2-)-O,O’][1R,2R-cyclohexanediamine-N,N’] platinum-II is 
mainly used in the treatment of colorectal cancer. It has some side-effects like 
progressive peripheral sensory neuropathy, mild acute neuropathy, diarrhea, vomiting and 
hematological suppression (Wiltshaw & Kroner, 1976).  
  
Figure 3: Structures
1.4 Synthesis of cisplatin
In 1845, Michel Peyrone synthesized cisplatin, 
structure, i.e., square planar st
Alfred Werner, for which he was awarded
Hambley, 2006). 
Early methods of cisplatin synthesis produced impur
unreliable. Many alterations aimed to improve the purity of the product, overall yield, and 
reaction time. Dhara (1970) 
shown in Figure 4, and this method is the basis for
cisplatin synthetic methods
(potassium iodide) to the starting material K
formed. Addition of NH3 
(NH3)2] which is collected, dried and then treated with aqueous AgNO
which causes the precipitation of A
filtrate containing [Pt(OH
precipitate out the final product cisplatin [PtCl
 
 
8 
 of Carboplatin & Oxaliplatin (Wiltshaw & Kroner, 1976).
 
but 50 years later its correct 
ructure with cis and trans configurations was
 the Nobel prize in 1913 (Alderen, Hall & 
e products and were 
reported a rapid method for the synthesis of cisplatin 
 the majority of the subsequent 
. In this method, by the addition of saturated solution of KI 
2(PtCl4), the tetraiodo analogue K
to K2PtI4 resulted in formation of the yellow product 
3 (silver nitrate
gI (silver iodide) that is filtered off and discard
2)2(NH3)2]2+ was treated with KCl (potassium chloride
2(NH3)2] as yellow powder.
 
 
 established by 
as 
2(PtI4) is 
cis-[PtI2 
), 
ed. The 
) to 
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Figure 4: Synthetic scheme for the Dhara synthesis of cisplatin (Dhara, 1970). 
1.5 Mechanism of Action 
After the discovery of the biological activity of cisplatin, much research was 
conducted for about 35 years in order to elucidate its mechanism of action. Major focus 
was on the DNA, i.e., the biological target of the drug, and examining the effects of 
cisplatin adducts formation on DNA dependent cellular functions.  
Cisplatin is believed to show its anticancer activity by interacting with DNA and 
inducing the programmed cell death. Cisplatin is introduced into cancer patients 
intravenously along with saline solution. Sixtyfive to ninetyeight percent of the cisplatin 
is found to be protein bound after one day of administration (Ivanov et al, 1998). Once 
cisplatin is administered, it enters the blood stream and remains intact due to the 
relatively high concentration of chloride ions (~100 mM). The un-dissociated compound 
then enters into the cell by passive diffusion and very little evidence shows that cisplatin 
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enters into the cell through active transport (Gately & Howell, 1993). Recent studies 
showed that cisplatin is transported actively through a copper transporter Ctr1 (Ishida, 
Lee, Thiele, & Herskowitz, 2002). 
 Inside the cell, the un-dissociated cisplatin molecule undergoes hydrolysis, 
wherein the chlorine ligand is replaced by a molecule of water. This process generates a 
positively charged species which react with the DNA bases, usually guanine, forming a 
mono-functional adduct. Hydrolysis occurs inside the cell due to a much lower 
concentration of chloride ion (~3-20 mM) and a higher concentration of water inside the 
cell. In-vitro studies reveal that mono-aquated forms of the platinum are responsible for 
ninetyeight percent of the drug binding to DNA.   
Insside the cell:   
Pt(II)(NH3)2Cl2 +H2O               [Pt(II)(NH3)2Cl(H2O)]+ + Cl- 
[Pt(II)(NH3)2Cl(H2O)]+ + H2O                 [Pt(II)(NH3)2(H2O)2]2+ + Cl- 
The N7 position on Guanine (G) is the electron rich site on DNA and 1, 2-GpG, i.e., 
adduct or crosslink formed by binding of cisplatin to two guanines on the same strand of 
DNA and 1, 2- ApG, i.e., adduct or crosslink formed by binding of cisplatin to adenine 
(A) and a guanine on the same strand of DNA, intra-strand crosslinks are the major 
adducts formed in the ratio of 2.5-4:1 respectively. Cisplatin forms bifunctional adducts 
with guanine-guanine and adenine-guanine which brings about the distortion of the DNA, 
i.e., bent towards the major groove and widening of the minor groove (Takahara, 
Rosenzweig, Frederick, & Lippard, 1995). This distortion is recognized by the specific 
types of proteins called High Mobility Group (HMG) proteins, which can either initiate 
DNA damage repair or signal for apoptosis, which is shown in Figure 5 (Fuertes, Castilla, 
 Alosnso, & Perez, 2002).
cycle arrest, replication inhibition
Lippard, 1999).  
Figure 5:
 
 Once inside the cell, cisplatin can bind to DNA, RNA, cellular proteins, enzymes 
or mitochondria. Interaction of cisplatin with mitochondria was unclear. The cytotoxicity 
of cisplatin is primarily due to its interaction with nucleophilic N
DNA to form DNA-DNA interstrand or intrastrand crosslinks and DNA
crosslinks as shown in Figure 6. 
lesions largely responsible for the cytotoxic action. 
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 The binding of HMG proteins to a minor groove results in
, transcription inhibition, and cell death
 Cytotoxic pathway of cisplatin (Lippert, 1999)
7 sites of 
-
However, evidence strongly favors intrastrand adducts as 
 
 cell 
 (Jamieson & 
 
. 
purine bases in 
protein 
 (A) 1, 2-intrastrand crosslink                    
(C) mono-functional adduct                        
1.6 Role of Ctr1 in cellular accumulation of Cisplatin
Ctr1 has been recognized as an important copper transporter that is present on the 
plasma membrane and distributed on a variety of intracellular membr
the several transporters that mediate the movement of copper ion across the plasma 
membrane. Recent studies have suggested a new role for Ctr1 in the cellular 
accumulation of the chemotherapeutic drug cisplatin and its analogues. Delet
yeast and mouse Ctr1 resulted in
cisplatin accumulation (Sinani, Adle, Kim, & Lee, 2007)
cell lines overexpressing 
and ATP7B are the two copper efflux transporters which are also involved in cisplatin 
efflux. Although this evidence suggest
Figure 6: Adducts formed after binding of cisplatin 
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                               (B) interstrand cross
                             (D) protein
 
anes. Ctr1 is one of 
 an increase in cisplatin resistance and a decrease in 
.   Human ovarian carcinoma 
Ctr1 exhibit an increase in cisplatin import into the cell. ATP7A 
s that cisplatin uptake and extrusion 
to DNA (Cepeda et al, 2007).
 
link 
-DNA crosslink 
ion of the 
are mediated 
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by copper transporters, the mechanism by which Ctr1 transports the chemically distinct 
copper and cisplatin is poorly understood.  
Like copper, in many types of cells, cis-DDP triggers the rapid degradation of 
Ctr1 and does that at much lower concentrations and more rapidly than copper. Figure 7 
illustrates the concept that, when assembled as a trimer, Ctr1 delivers a series of stacked 
rings of methionines, histidines, and cysteines that take part in transchelation reactions to 
ensure the regulated movement of copper through Ctr1.  The pore formed by the Ctr1 
trimer is only 8 Å in diameter. This is large enough to accommodate copper but initially 
seems too small to allow passage of the platinum-containing drugs. However, 
transmembrane proteins of this type can be quite flexible, and the wall of the pore is 
potentially quite expandable. Platinum drugs have square planar configuration and it may 
be the ability of each to bind to one or more sulfur atoms of the methionine rings in Ctr1 
and to undergo transchelation reactions, which makes them transportable by Ctr1. Loss of 
Ctr1 is associated with cisplatin resistance both in-vitro and in-vivo.  
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Figure 7: Schematic illustration of the trimeric pore of CTR1 (Howell, Safaei, Larson, & 
Sailor, 2010). 
1.7 Cisplatin Resistance 
 Even though cisplatin is very effective in cancer treatment, it faces problems 
which most of the drugs face, i.e., drug resistance. Intracellular platinum concentration 
plays a key role in the drug resistance. Resistance occurs when cells once destroyed by a 
particular drug no longer respond to the same drug. Drug resistance is a major 
complication in cancer chemotherapy and accounts for the failure of chemotherapy to 
cure cancer in the majority of patients. Cisplatin resistance leads to reduced DNA damage 
and this resistance is developed through: 
1. Reduced intracellular drug accumulation: The cause of reduced cisplatin 
accumulation in cisplatin-resistant cells is due to inhibition of drug uptake or 
increase in drug efflux or both. Even though cisplatin is not transported by the 
  
15 
sodium potassium ATPase pump, its inhibitor Ouabain inhibits drug uptake and 
this suggests that cell membrane potential is the cause of the drug accumulation 
(Michael & Hoeschele, 1973). 
2. Increased inactivation by thiol-containing molecules: Cisplatin is inactivated 
by many cytoplasmic constituents including nucleophilic GSH and cysteine-rich 
metallothionein (Guo & Sadler, 1999). The concentration of the GSH levels 
increases with chronic exposure of cisplatin and induces resistance by decreasing 
the level of cisplatin available for interacting with DNA. 
3. Increase in DNA damage repair: Another way that cells can become resistant to 
cisplatin is to have an enhanced ability to remove cisplatin-DNA adducts and to 
repair cisplatin-induced lesions in DNA. Nuclear Excision Repair (NER) pathway 
is the major pathway which helps in the removal of the cisplatin DNA adducts. 
Cellular defects in this pathway resulted in the hypersensitivity towards cisplatin 
(Thor et al., 1998). This ability is shown by certain DNA repair proteins. An 
example of such protein is XPE-BF (xeroderma pigmentosum group E binding 
factor). When the levels of this protein go up, cisplatin resistance develops. 
4. Inhibitors of the apoptosis: Survivin and XIAP are the molecules which are 
found to inhibit the apoptosis pathway. These are the direct effectors of the 
apoptosis irrespective of the DNA damage pathway (Asselin, Mills, & Tsang, 
2001). 
5. Dysfunction of the tumor suppressor p53: Stabilization and activation of the 
p53 is responsible for apoptosis. Defects in the gene expression result in the 
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development of tolerance to the cisplatin because of the failure of the apoptosis 
(Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991). 
1.8 Binding of Cisplatin to DNA Bases 
Many efforts have been made in developing new anticancer drugs which can 
overcome the cisplatin resistance or enhance the activity of the drug. Many 
computational studies have been put forward in the past and none have been successful in 
developing the understanding of the features controlling the interaction of the Pt moiety 
with the nucleotide bases (Baik, Friesner, & Lippard, 2003). The models proposed by 
computational methods studied the electronic structure changes resulting from Pt−N bond 
formation, such as the influence of platination on base pairing and proton affinity. 
Cisplatin is mainly found to interact with purine bases, such as adenine and guanine, than 
pyrimidines, such as thymine and cytosine. Among purines, it preferentially binds to 
guanine than adenine. 
1.9 Cisplatin binds more preferably to guanine than adenine. Why? 
 Many experiments have been performed in order to determine why cisplatin 
binds more preferably to guanine than adenine. Theoretical studies of kinetic behavior of 
cisplatin binding to guanine and adenine were performed by Baik et al (2003), who 
proposed two possible reasons for this behavior, i.e., the hydrogen bonding and the 
electronic interactions between the metal center and the lone-pair orbital of N7 of 
nucleotide base. Using a series of experimental studies, it was concluded that N7 
platination of guanine is both thermodynamically and kinetically more favorable than N7 
platination of adenine (Baik, Friesner, & Lippard, 2003). 
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 The hydrogen bond between an amine ligand of platinum and the oxo group of 
guanine plays an important role in stabilizing the Pt-guanine adduct when compared to 
Pt-adenine adduct. In the Pt-adenine adduct, Pt-ammine ligand acts as a hydrogen bond 
donor, which is not energetically favorable (Baik, Friesner, & Lippard, 2003). 
Coordination of Platinum compounds resulted in the formation of GG adducts 
(60-65%), and AG adducts (20-25%) (Legendre, Chottard, & Kozelka, 1998); the GA 
adducts were not detected for a long time, but the recent findings of Chottard et al 
revealed the presence of monoadducts that led to a slow chelation within GA sequences 
(Monjardet, Bombard, Chottard, & Kozelka, 2003).  Chottard and his research group 
performed many computational studies to study the reaction rates of cisplatin with two 
oligonucleotides containing GG and AG sequences. They came up with many 
conclusions of which they found that the accessibility is the main factor in determining 
the sequence dependent binding of Pt compounds to DNA, i.e., the size of the 
neighboring bases can influence the reactivity. The flanking bases or adjacent bases can 
influence reactivity of guanine via steric clashes (Monjardet, Elizondo, Chottard, & 
Kozelka, 2002). If a ligand is bulkier, then we could expect less reaction of A, due to the 
steric clashes between the amine at sixth position and the ligand, when compared to G, 
which has less bulky O instead.  
Another main finding was that the hydrogen bonding plays an important role in Pt 
compounds binding to adenine and guanine residues of DNA. Their results suggest that 
the ligand cis to the incoming site can influence the reaction through hydrogen bonding 
and that G reacts ~6 times faster than A, with the diaqua form of cisplatin which could be 
the form that reacts with DNA (Monjardet, Elizondo, Chottard, & Kozelka, 2002). 
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 The preference for the nucleotide base depends on the size and type of ligand 
present on the platinum. The platinum can coordinate at sites other than N7 and N1 of 
adenine; the Bierbach experiments on PT-ACRAMTU ([Pt(en)Cl(ACRAMTU-S)](NO3)2 
(en = ethane-1,2-diamine, ACRAMTU =1-[2-(acridin-9-ylamino)ethyl]-1,3-
dimethylthiourea) showed unusual binding to the N3 position (Bierbach & Farrell, 1997).   
1.10 Previous Research 
A bulky platinum triamine complex, [Pt(Me5dien)(NO3)]NO3 (Me5dien = 
N,N,N’,N’,N’’-pentamethyldiethylenetriamine), was reacted with N-acetylmethionine 
(N-AcMet) and guanosine 5’ monophosphate (5’-GMP), which led to the formation of 
two rotamers of [Pt(Me5dien)(5’-GMP-N7)]+ with 5’-GMP and [Pt(Me5dien)(N-AcMet-
S)]+ with N-AcMet. The platinum complex was found to react faster with GMP when 
compared to N-AcMet (Sandlin, Starling, & Williams, 2010). The slow reactivity of N-
AcMet was attributed to the steric clashes between the N-AcMet and the methyl group of 
the bulky ligand Me5dien.  
The opposite trend was observed when a less bulky platinum complex, 
[Pt(dien)Cl]Cl was used, i.e., N-AcMet reacts faster than 5’-GMP (Djuran, Lempers, & 
Reedijk, 1991). It was anticipated that the bulk of the platinum complex affects the 
reactivity. It was believed that the platinum complexes with sufficient bulk are selective 
to DNA rather than proteins (Sandlin, Starling, & Williams, 2010). 
1.11 Our Approach 
Our research focus is to examine how the bulk of the platinum (II) complexes 
affects the reaction rate with nucleotide bases. Two platinum (II) triamine complexes, 
 [Pt(Me5dien)(NO3)]NO3 which 
which has a less bulky ligand dien,
whose structures are represented in Figures 8 and 9.
study all the reactions. Dynafit software was used to study the rate constants of the 
reactions.  
 
Figure 8: Structures of 
 
Figure 9: Structures of 5’
s 
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has a bulky ligand Me5dien and [Pt(dien)(NO
 were reacted with 5’-AMP and 5’-GMP DNA
 NMR spectroscopy was used to 
[Pt(Me5dien)(NO3)]NO3 and [Pt(dien)(NO
-Adenosine monophosphate & 5’-Guanosine monophosphate
3)]NO3 
 bases, 
 
3)]NO3 
 
. 
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2. EXPERIMENTAL SECTION 
2.1 Reagents used 
Potassium tetrachloroplatinate(II) (K2PtCl4), N,N,N’,N’,N” -
pentamethyldiethylene triamine (Me5dien), silver nitrate (AgNO3), sodium 
trifluoromethane sulfonate (sodium triflate), deuterium oxide (D2O), and potassium 
iodide (KI), were from Aldrich. 5’-Adenosine monophosphate (5’-AMP), 5’-Guanosine 
monophosphate (5’-GMP), and diethylenetriamine (dien) were from Acros Organics. All 
the reagents were used as such without any further purification. 
2.2 Synthesis of platinum diethylenetriamine dinitrate or [Pt(dien)(NO3)]NO3 
The synthesis of platinum diethylenetriamine dinitrate involves two steps: the 
synthesis of platinum diethylenetriamine dichloride and the reaction of synthesized 
platinum diethylenetriamine dichloride with silver nitrate (Guiliano, Matilde, & Bruno, 
1995). 
(i) Synthesis of chlorodiethylenetriamine platinum (II) chloride:  
0.1 g of Potassium tetrachloroplatinate (K2PtCl4) was dissolved in 30 mL of 
deionized water. To this solution, 1.0 mL of (98%) diethylenetriamine was added. The 
pH of the solution was adjusted to 3 by the addition of 1 M HCI. The solution was 
refluxed for about 6 hours. The resulting yellow-colored solution was filtered, 
concentrated to 4 mL, and left overnight in a refrigerator. The crystals were removed by 
filtration, washed with a small amount of ethanol, and air-dried. The pure complex was 
obtained by recrystallization from a small amount of water (Guiliano, Matilde, & Bruno, 
1995). 
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(ii) Reaction of Platinum diethylenetriamine dichloride with silver nitrate: 
100 mg of Platinum diethylenetriamine dichloride was added to an amber vial. 92 
mg of silver nitrate and 20 mL deionized water were also added. The sample was then 
allowed to stir overnight. The solution was filtered into a 50 mL round bottomed flask 
using syringe filtration. The product platinum diethylenetriamine dinitrate was obtained 
by evaporating the solution using a rotary evaporator and was then stored and used for 
further reactions (Guiliano, Matilde, & Bruno, 1995). 
2.3 Synthesis of platinum pentamethyldiethylene triaminedinitrate or 
[Pt(Me5dien)(NO3)]NO3 
Platinum pentamethyldiethylenetriamine dinitrate was synthesized by using a 
method described by Cini et al. (1998), except for the use of silver nitrate instead of silver 
triflate. The synthesis involves two steps: The synthesis of [Pt(Me5dien)I]2(Pt2I6) 
followed by the reaction of synthesized [Pt(Me5dien)I]2(Pt2I6) with silver nitrate.  
(i) Synthesis of [Pt(Me5dien)I]2(Pt2I6):  
0.5 g of potassium tetrachloroplatinate (K2PtCl4) was dissolved in 5 mL of 
deionized water. 0.82g of potassium iodide (KI) was added at 50ºC. To this solution, 250 
µL of pentamethyl diethylenetriamine was added. The solution was allowed to stir for 
one hour at 50ºC on a magnetic stirrer. Yellow-green precipitate was filtered off using 
gravitational filtration. The separated precipitate was washed with water and air dried for 
2 days (Cini, Intini, Maresca, Pacifico, & Natlie, 1998). 
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(ii) Reaction of [Pt(Me5dien)I]2(Pt2I6)  with silver nitrate:  
300 mg of [Pt(Me5dien)I]2(Pt2I6) was added to a 20 mL of deionized water in an 
amber vial. 98.5 g of silver nitrate was also added. The resultant mixture was allowed to 
stir overnight on a magnetic stirrer. The solution was filtered using syringe filtration and 
the filtrate was evaporated to dryness using a rotary evaporator. The obtained product 
was stored and used as and when needed.  
2.4 Preparation of Stock Solutions 
• Stock solution of Pt(Me5dien): 4.92 mg of Platinum pentamethyldiethylene 
triamine dinitrate-Pt(Me5dien)(NO3)2 [Mol Wt – 492.45 g] was dissolved in 1 mL 
of D2O to obtain a 10 mM solution. 
• Stock solution of Pt(dien): 4.22 mg Platinum diethylenetriamine dinitrate-
Pt(dien)(NO3)2 [Mol Wt – 422.5 g] was dissolved in 1 mL of D2O to obtain a 10 
mM solution. 
• Stock solution of 5’-AMP: 3.47 mg of 5’-Adenosine monophosphate (5’-AMP) 
[Mol Wt – 347.2 g] was dissolved in 1 mL of D2O to obtain a 10 mM 
concentrated solution. 
• Stock solution of 5’-GMP: 4.07 mg of 5’-Guanosine monophosphate (5’-GMP) 
[Mol Wt – 407.19 g] was dissolved in 1 mL of D2O to obtain a 10 mM 
concentrated solution. 
• Stock solution of sodium triflate: Molecular weight of Sodium triflate is 172.2 g. 
1.72 mg sodium triflate was dissolved in 1 mL of D2O to obtain a 10 mM 
concentrated solution. 
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Solutions of required concentrations were prepared and used when needed. 
2.5 Methods 
A JEOL Eclipse 500 MHz Nuclear Magnetic Resonance was used to characterize 
the products. Deuterium oxide (D2O) was used as solvent for characterization. 1H-NMR 
spectroscopy was used to study all the reactions. Heteronuclear Multiple Quantum 
Coherence (HMQC) Spectroscopy was used to study the products formed by the reaction 
of Pt(Me5dien) and AMP. 
Solutions used for pH adjustment: 
 1% deuterated nitric acid and 1% sodium deuteroxide were used to adjust the pH 
of all the solutions used.  
Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-Adenosine monophosphate: 
A 300 µL aliquot of a 5 mM stock solution of Pt(Me5dien) was mixed with a 300 
µL aliquot of a 10 mM stock solution of 5’-AMP. The NMR tube was kept in a water 
bath for about half an hour, maintained at 25ºC. The pH of the solution was adjusted to 4 
before taking spectra.  
Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-Guanosine monophosphate: 
A 300 µL aliquot was taken from a mixture of 10 mM 5’-GMP and 100 mM 
sodium triflate and added to a 300 µL aliquot of a 20 mM Pt(Me5dien). The pH of both 
solutions was adjusted to 4 prior to mixing. 1H-NMR kinetics scan was used study the 
reaction. This kinetics method was made to scan every 10 min for 2 hours. 
Reaction of [Pt(dien)(NO3)]NO3 and 5’-Adenosine monophosphate: 
A 400 µL aliquot of 10mM [Pt(dien)(NO3)]NO3 was added to the mixture of 100 
µL aliquot of 10 mM 5’-AMP and 500 µL of D2O . The pH of both solutions was 
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adjusted to 4 prior to mixing. 1H-NMR kinetics scan was used study the reaction. This 
kinetics method was made to scan every 5 min for 1.5 hours.   
Reaction of [Pt(dien)(NO3)]NO3 and 5’-Guanosine monophosphate: 
A 30 µL aliquot of 10mM [Pt(dien)(NO3)]NO3 was added to the mixture of 15 µL 
aliquot of 10 mM 5’-GMP and 955 µL of D2O. The pH of both solutions was adjusted to 
4 prior to mixing. 1H-NMR kinetics scan was used study the reaction. This kinetics 
method was made to scan every 5 min for 1 hour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.1 Reaction of [Pt(Me5dien)(NO
The 1H-NMR spectrum was obtained immediately after mixing solutions of 2.5 
mM of [Pt(Me5dien)(NO3
adjusted to 4 prior to mixing.
Figure 10: (C) is the product for
There are two possibilities of Pt(Me
coordinated to N7 position 
Four sets of new resonances were observed:
two with downfield shifted H
chemical shifts of H8 and H
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3. RESULTS 
3)]NO3 and 5’-AMP 
)]NO3 and 5 mM of 5’-AMP. The pH of both solutions was 
 
 
med by the coordination of [Pt(Me5dien)(NO
complex (A) at N7 position of (B). 
5dien) complex to react with AMP. It can get 
or at the N1 position of Adenine as shown in Figures 10 & 11
 two with downfield shifted H
2 signals according to the HMQC spectrum. The downfield 
2 protons were observed due to N7 and N1 coordination
 
3)]NO3 
. 
8 signals and 
 
 respectively. New product signals appear in the NMR spectrum corresponding to two 
different coordinations. 
 
 
Figure 11: (C) is the product formed by the 
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coordination of [Pt(Me5dien)(NO
complex (A) at N1 position of (B). 
 
3)]NO3  
 Figure 12: Partial NMR spectra of the reaction of Pt(Me
The NMR spectrum did not show any signal for the product on 
which indicates that there was no reaction between AMP and [Pt(Me
As in Figure 12, the spectrum showed three prominent peaks a
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5dien) and 5’-AMP on day 1 
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the 
5dien)(NO
t the following chemical 
 
& 
first day, 
3)]NO3. 
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shifts: H1’ at 6.06 ppm, H2 signal at 8.23 ppm, H8 signal at 8.45 ppm. These peaks were 
corresponding to unreacted AMP.  
After 12 days, many new peaks appeared in the NMR spectrum. HMQC 
spectroscopy was used to study the reaction of [Pt(Me5dien)(NO3)]NO3 and AMP. This is 
a Two-Dimensional NMR spectroscopy technique, a correlation technique that allows the 
determination of carbon and hydrogen connectivity. 
In the spectrum obtained after 12 days, the four new peaks found downfield to the 
H8 peak of the unreacted AMP, were assigned as H8 and H2 product peaks and this 
assignment was confirmed based on the results obtained by HMQC experiment. The two 
H8 peaks were found at chemical shifts of 9.29 and 9.21 ppm and two H2 peaks at 8.41 
and 8.60 ppm. H8 peaks were found to be more downfield than H2 peaks. This downfield 
shift of the H8 and H2 product peaks from H8 of unreacted AMP indicates the N7 and N1 
coordination, respectively. Two sets of resonances are observed for each H8 and H2 
signal, due to slow rotation around the Pt-N7 or Pt-N1bond. 
The chemical shifts of two other peaks found in between H8 and H2 of the 
unreacted AMP are at 8.26 and 8.29 ppm. These new peaks are assigned as the H2s of N7 
coordination. The H8 peaks corresponding to the N1 coordination were partially obscured 
by unreacted AMP. The product peak of H1’ was observed at 6.14 ppm, which is 
downfield to H1’ of unreacted AMP. The spectrum suggests that the reaction of 
Pt(Me5dien) with AMP resulted in approximately equal reaction at both N7 and N1 
positions. The reaction of Pt(Me5dien) with AMP was very slow in that it took 12 days to 
observe the product signals in the NMR spectrum. 
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The rate of reaction was estimated to be 0.00003 M-1s-1. The result described by 
R.D Sandlin et al (2010), showed the rate constant of 0.02 M-1s-1 for the reaction of 
[Pt(Me5dien)(NO3)]NO3 and 5’-GMP at concentrations of 3.33mM each, which suggests 
that the cisplatin analog [Pt(Me5dien)(NO3)]NO3 reacts at a very slow rate with AMP 
when compared to GMP (Sandlin, Starling, & Williams, 2010). 
3.2 Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-AMP at different temperatures 
A 500 µL aliquot of [Pt(Me5dien)(NO3)]NO3 (40 mM) solution was mixed with 
250 µL of 5’-AMP (40 mM) and 250 µL of sodium triflate 400 mM. The pH of the 
solution was adjusted to 4 and the NMR tube was stored in a water bath maintained at 
25ºC. After 30 days, the pH was adjusted to 4 and 1H-NMR scan was used to study the 
reaction at different temperatures of 25, 40, 60, and 80 ºC and the spectra are shown in 
Figure 13. 
The NMR spectra were analyzed for peak broadening of H8s and H2s of the 
products formed in the reaction. There was no significant peak broadening or coalescence 
when the temperature was increased from 25ºC to 40, 60, 80 ºC, indicating that the 
exchange between the rotamers is very slow. [Pt(2,2’-bipiperidine)(5’-GMP)2] also 
showed similar results due to slow rotation (Susan, Intini, Natlie, & Marzilli, 1998). From 
the experiments by Reily and Marzilli (1986), peak broadening of the H8 peaks of the 
Pt(en)(5’-dAMP-N7)  complex was observed when the temperature was increased, which 
is in contrast with the Pt(Me5dien) and AMP reaction (Reily & Marzilli, 1986). 
 Figure 13: Partial NMR spectra showing the reaction of Pt(Me
3.3 Reaction of [Pt(Me5dien)(NO
  The [Pt(Me5dien)(NO
mM and 3.33 mM concentrations respectively. The pH of the solutions was adjusted to 4 
using a suitable buffer solution before mixing. The 
run the reaction which scans the 
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5dien) and AMP at 
temperatures of 25, 40, 60, and 80 ºC. 
3)]NO3 and 5’-GMP 
3)]NO3 complex was allowed to react with 5’
1H-NMR Kinetics scan was used to 
reaction every 10 min for 2 hours. 
 
-GMP at 3.33 
 As shown in Figure 14, t
coordination of [Pt(Me5dien)(NO
 
 
Figure 14: (C) is the product 
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he downfield shift of product H8 peak indicates the N
3)]NO3 complex to guanine. 
formed by the coordination of [Pt(Me5dien)(NO
 (A) at N7 position of 5’-GMP (B). 
7 
 
3)]NO3 
 Figure 15: Partial NMR spectrum of reaction of [Pt(Me
In the above spectrum
signals at chemical shifts of 5.85 and 8.05 ppm, which correspond to H
hydrogen from the deoxyribose ring of GMP and H
reaction of Pt(Me5dien) and AMP, wherein the product peak did not appear until after 12 
days, in this reaction the product peak started showing up within 10 min. The initial 
product signal was observed at 8.85 ppm.
The reaction within 70 min interval shows prominent signals
product. The H8 signals ap
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Me5dien ligand does not have a C2 symmetry (Cini, Intini, Maresca, Pacifico, & Natlie, 
1998), thus these peaks were assigned as rotamers of the complex [Pt(Me5dien) (5’-
GMP-
 
N7)]+ (Sandlin, Starling, & Williams, 2010). Two sets of resonances are observed 
for H8 signal due to slow rotation around the Pt-N7 bond. The reaction proceeds in the 
forward direction leading to the formation of the product. The product peak intensity 
increases with time. It is clearly shown within 120 min interval that the H8 peak height of 
unreacted 5’-GMP decreased and the H8 and H1’ product peak heights of product 5’-GMP 
increased with time. 
 The [Pt(Me5dien)(NO3)]NO3 complex was found to coordinate at N7 position of 
guanine and the rate of reaction was previously estimated to be 0.02 M-1s-1 (Sandlin, 
Starling, & Williams, 2010). 
3.4 Reaction of [Pt(dien)(NO)3]NO3 and 5’-AMP 
The [Pt(dien)(NO3)]NO3 complex was allowed to react with 5’-AMP at a 
concentration of 1 mM and 4 mM respectively. The pH of the solutions was adjusted to 4 
using a suitable buffer solution before mixing. The 1H-NMR kinetics scan was used to 
run the reaction which scans for every 5 min for 1.5 hours. 
As shown in Figure 16, the downfield shift of product H8 peak indicates the N7 
coordination of [Pt(dien)(NO3)]NO3 to AMP. 
 Figure 16: (C) is the product formed by the coordination of 
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[Pt(dien)(NO
position of AMP (B). 
 
3)]NO3 (A) at N7 
 Figure 17: Partial NMR spectrum of reaction of [Pt(dien)(NO
In the above stacked NMR spectra,
peaks at chemical shifts of 8.20 and 8.42 ppm, whic
AMP.  The peak corresponding to H
spectrum within 20 min of time. The initial product peak of H
and H2 was found at 8.21 ppm. The H
Pt(en)(5’-dAMP-N7) also showed 
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 Figure 17, the spectrum at 10 min shows two 
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8 of product 5’-AMP was found downfield in the 
8 was found at 8.87 ppm 
8 product peak was broader. The product H
a similar broader peak in the experiment c
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8 peak of 
onducted by 
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Reily and Marzilli (1986) due to restricted rotation around Pt-N7 bond (Michael & Luigi, 
1986). 
The peak height of product H8 and H2 increased with time and the intensity of H8s 
& H2s of the unreacted AMP decreased significantly with time. The rate of reaction was 
estimated to be 0.188M-1s-1. 
3.5 Reaction of [Pt(dien)(NO3)]NO3 and 5’-GMP  
The [Pt(dien)(NO3)]NO3 complex was allowed to react with 5’-GMP at 0.3 mM 
and 0.15 mM concentrations respectively. The pH of the solutions was adjusted to 4 
using a suitable buffer solution before mixing. The 1H-NMR kinetics scan was used to 
run the reaction which scans the reaction every 5 min for 1 hour. The downfield shift of 
product H8 indicates the N7 coordination of Pt(dien) to GMP which is shown in Figure 
18. 
 Figure 18: (C) is the product formed by the coordination of 
In the stacked partial NMR spectra,
interval showed peaks at chemical shifts of 5.95 and 8.73 ppm. The 
sugar of GMP was at 5.9 ppm and the H
and H1’ signals of unreac
concentration; they are indistinguishable from 
tends to increase prominently with time in the spectra within 35 and 60 min. 
The rate of reaction was 
of Pt(dien) and GMP were used,
interval. So, as to observe the reaction rate, the reaction was started with very low 
concentrations of 0.3 mM of Pt(dien
concentration, the H8s and H
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[Pt(dien)(NO
position of GMP (B). 
 Figure 19, the spectrum within 
H1’ of
8 of guanine was at 8.73 ppm. The distinct H
ted GMP are not seen in the spectra because of the low 
the noise. The intensity of product signal 
estimated to be 7.32 M-1s-1. When higher concentrations 
 the reaction almost reached completion within a 
) and 0.15 mM of GMP. Even at this low 
1’ of the unreacted GMP could not be seen. 
 
3)]NO3 (A) at N7 
a 10 min 
 deoxyribose 
8s 
 
10 min 
 Figure 19: Partial NMR spectrum of reaction of [Pt(dien)(NO
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35 & 60 min interval. 
 
5’-GMP at 10, 
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Table 1: Rate constants of cisplatin analogs with nucleotide bases. 
 
 
  
Cisplatin analog Nucleotide Rate Constant (M-1s-1) 
[Pt(dien)(NO3)]NO3 5’-GMP 7.32 
[Pt(dien)(NO3)]NO3 5’-AMP 0.188 
[Pt(Me5dien)(NO3)]NO3 5’-GMP 0.02 
[Pt(Me5dien)(NO3)]NO3 5’-AMP 0.00003 
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4. DISCUSSION 
In our research, we reacted the cisplatin analogs, Pt(Me5dien) and Pt(dien) with 
the 5’-AMP and 5’-GMP nucleotides. We used NMR spectroscopy to study the reaction 
patterns. Dynafit software was used to find the rate constants of reactions. Our main 
focus was to study how the bulk significantly affects the reaction rate of cisplatin analogs 
when reacted with nucleotides. 
Previous research was based on the reaction of a bulky triamine complex 
[Pt(Me5dien)NO3]NO3 with 5’-GMP and N-acetylmethionine separately. The separate 
reactions resulted in a slower reaction with N-AcMet than with 5’-GMP. The competition 
reactions showed a significant decrease in the formation of [Pt(Me5dien)(N-AcMet-S]+ 
complex when compared to [Pt(Me5dien)(5’-GMP)]+ complex (Sandlin, Starling, & 
Williams, 2010). 
Previously, [Pt(dien)Cl]Cl was reacted with 5’-GMP and N-acetylmethionine and 
produced an exact opposite result, i.e., it reacts faster with N-AcMet when compared to 
GMP (Djuran, Lempers, & Reedijk, 1991), because the size of the Me5dien ligand 
impacted these targets differently. We hypothesized that the AMP ligand would be 
affected more than the GMP ligand by the increased size of the Me5dien, as the former 
has the larger amino group at the sixth position. 
 In our research, [Pt(Me5dien)NO3]NO3 was reacted with both 5’-AMP and 5’-
GMP in separate reactions at pH 4. When the [Pt(Me5dien)NO3]NO3 complex was 
reacted with 5’-GMP, two new sets of resonances were observed. The resonances were 
assigned to two rotamers of [Pt(Me5dien)(5’-GMP-N7)]+ and the rate constant was 
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previously estimated to be 0.02 M-1s-1 (Sandlin, Starling, & Williams, 2010). The 
downfield shift of H8 of product indicates the N7 coordination.  
When the [Pt(Me5dien)NO3]NO3 complex was reacted with 5’-AMP four new 
sets of resonances appeared, each with one signal downfield from the H8 and H2 of the 
unreacted AMP. These peaks were assigned as two H8s and two H2s by performing a 2-D 
Heteronuclear Multiple Quantum Coherence Spectroscopy. The downfield shifted H8 and 
H2 resonances are the results of N7 and N1 coordination respectively. The rate constant 
was estimated to be 0.00003 M-1s-1. 
When compared to the reaction of Pt(Me5dien) and AMP, the reaction of 
Pt(Me5dien) and GMP proceeds much faster, i.e., the ratio of their rate constants is 1: 
~650. The bulk of Me5dien ligand significantly slowed the reaction with AMP more than 
with the GMP such that it took almost 12 days for the product signals to appear whereas 
for Me5dien and GMP, it just took 10 min for the product peak to show up in the NMR 
spectrum. 
The [Pt(dien)NO3]NO3 complex was reacted with both 5’-AMP and 5’-GMP in 
separate reactions at pH 4. When the [Pt(dien)NO3]NO3 complex was reacted with 5’-
GMP, a peak corresponding to H8 of product appeared and the intensity was found to 
increase with time. The reaction was so fast that the unreacted GMP got mixed with noise 
of the NMR spectrum. The rate constant of the reaction was estimated to be 7.32 M-1s-1. 
When the [Pt(dien)NO3]NO3 complex was reacted with 5’-AMP, the H8 product 
peak appeared downfield from the H8 peak of unreacted AMP, indicating the N7 
coordination. The rate constant of the reaction was estimated to be 0.188 M-1s-1.  
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Several previous studies from the Marzilli lab with 5’-AMP and 5’-GMP 
concluded that restricted rotation around the Pt-N7 bond was observed for 5’-GMP when 
the ligand is bulky. Later, they found that the products from reaction with the AMP, 
showed restricted rotation around the Pt-N7 bond even when the ligand is not bulky, 
whereas the product from reaction with GMP showed restricted rotation when the ligand 
is bulky (Reily &Marzilli, 1986). The experiments by Cramer and Dahlstrom revealed 
that the complexes with a bulky ligand group shows restricted rotation, which is 
evidenced by the appearance of two H8 signals. When 195Pt-NMR spectroscopy was used, 
the Pt compounds were found to preferably bind N7 when compared to N1 of 5’-AMP by 
a ratio of ~10:1 and these observations suggest appreciable steric effects of the 6-NH2 
group of 5’-AMP and the high selectivity of Pt compounds for guanine residues may be 
because of the steric effects (Reily &Marzilli, 1986). 
Our results are in agreement with the findings of Reily and Marzilli, that the 
product peak of Pt(dien) and AMP is broader due to the restricted rotation around the Pt-
N7 bond. The reaction with Me5dien and GMP showed two product peaks, which is 
supported by the findings of Reedjik and group (Reedjik, 1999). According to a study 
conducted by Bierbach, monofunctional PT-ACRAMTU uniquely targets the N3 position 
of adenine present in the minor groove of DNA, which is in contrast to traditional 
cisplatin analogs that bind to N7 or N1 position of adenine.   
The reaction of Pt(dien) and GMP was faster in comparison to reaction of Pt(dien) 
and AMP, which indicates that the Guanine is the primary target and Adenine is the 
secondary target of Pt(dien) ligand. Adenosine is considered less reactive when compared 
to guanosine most probably because of the presence of the bulkier NH2 (amine) group of 
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the adenine than the O (oxo) group of guanine at the sixth position (Green, Garner, & 
Orton, 1992). Me5dien, which is bulky, does not have the ability to form a hydrogen bond 
to the purine bases whereas dien, which is non-bulky, does. However, if hydrogen 
bonding is a key factor in the reactivity, then we would expect the Me5dien ligand to 
disfavor GMP more than AMP since the former is thought to participate in hydrogen 
bonding with ligands cis to the available coordination site (Legendre, Bas, Kozelka, & 
Chottard, 2000). The decrease in the reactivity of Me5dien with adenine more than with 
guanine is accounted towards steric effects rather than hydrogen bonding; steric effects 
have previously been found to influence reactivity of cisplatin metabolites with DNA 
sequences (Monjardet, Elizondo, Chottard, & Kozelka, 2002). 
In conclusion, the reaction rates of cisplatin analogs, Pt(Me5dien) and Pt(dien) 
with 5’-GMP and 5’-AMP were studied using NMR spectroscopy. 5’-GMP reacts faster 
than 5’-AMP with both platinum complexes. The bulk of the Me5dien ligand significantly 
slows reaction with both GMP and AMP when compared to the dien ligand. Pt-Me5dien 
leads to reaction at both N7 and N1 positions of AMP. The reaction was approximately 
equal at both N7 and N1 positions, which was confirmed by the data obtained by using 
HMQC. Bulk would slow down the reaction with AMP more than GMP. GMP is ~40 
times faster than AMP when reacted with Pt(dien) but ~700 times faster than AMP with 
Pt(Me5dien). 
 It is our understanding that platinum compounds with bulky amine ligands may 
slow down the reaction of AMP when compared to GMP. Platinum was found to 
coordinate both at sites other than N7, i.e., at N1 or N3. Since GG adducts are favored 
~3:1 over AG adducts by cisplatin metabolites, we would expect that cisplatin analogs 
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with larger amine ligands would show a substantial favoring of GG adductss over other 
types of intrastrand crosslinks.  
The order of reactivity of Cisplatin analogs with nucleotides was found to be 
Pt(dien)(GMP) > Pt(dien)(AMP) > Pt(Me5dien)(GMP) > Pt(Me5dien)(AMP). 
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